|View printer-friendly version|
|Array BioPharma to Report Financial Results for the Third Quarter of Fiscal 2012 on April 30, 2012|
BOULDER, Colo., Apr 23, 2012 (BUSINESS WIRE) --Array BioPharma Inc. (Nasdaq:ARRY) will report financial results for the third quarter of fiscal 2012 on Monday, April 30, 2012, and will hold a conference call on Tuesday, May 1, 2012 at 9:00 a.m. Eastern time to discuss these results. Michael Carruthers, Chief Financial Officer, and Kevin Koch, Ph.D., President and Chief Scientific Officer, will lead the call.
A replay of the call will be available as a webcast on www.arraybiopharma.com
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Array has four core proprietary clinical programs: ARRY-614 for myelodysplastic syndromes, ARRY-520 for multiple myeloma, ARRY-797 for pain and ARRY-502 for asthma. In addition, Array has 10 partner-funded clinical programs including two MEK inhibitors in Phase 2: selumetinib with AstraZeneca and MEK162 with Novartis. For more information on Array, please go to www.arraybiopharma.com.
SOURCE: Array BioPharma Inc.
Array BioPharma Inc.